InnoCare Pharma Limited (INCPF)

3.2600 0.0000 (0.00%) At close: 09:40AM EDT

InnoCare Pharma Limited

Building 8
No. 8 Life Science Park Road Zhongguancun Life Science Park Changping District
Beijing 102206
China
86 10 6660 9999
https://www.innocarepharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1,089

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jisong Cui Ph.D.	Co-Founder, Chairwoman & CEO	1.03M	N/A	1964
Dr. Renbin Zhao Ph.D.	VP of Regulatory Affairs & Clinical Development and Executive Director	401.04k	N/A	1969
Mr. Xin Fu	Chief Financial Officer	N/A	N/A	N/A
Mr. Nan Gao	Chief Operating Officer	N/A	N/A	1974
Dr. Xiangyang Chen Ph.D.	Chief Technology Officer	N/A	N/A	1968
Ms. Junsu Wang	General Counsel	N/A	N/A	1977
Dr. Xiang-Yang Zhang M.D.	Chief Medical Officer	N/A	N/A	1963
Mr. Davy Ouyang Ph.D.	VP & Head of Biology	N/A	N/A	N/A
Mr. Jeff Chen	Chief Commercial Officer	N/A	N/A	N/A
Ms. Pui Shan Lee	Company Secretary	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. The company has a clinical development collaboration with ArriVent Biopharma, Inc. to evaluate the anti-tumor activity and safety of ICP-189 combined with furmonertinib in patients with advanced non-small cell lung cancer. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

Corporate Governance

InnoCare Pharma Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.